Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia

Haematologica. 2017 Feb;102(2):e43-e46. doi: 10.3324/haematol.2016.155069. Epub 2016 Oct 20.

Affiliations

¹ Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Recife, Brazil.
² Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
³ Department of Internal Medicine, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil.
⁴ Department of Internal Medicine, Hematology and Hemotherapy Foundation of Pernambuco, Recife, Brazil.
⁵ Department of Genetics, Federal University of Pernambuco, Recife, Brazil [email protected].
⁶ Department of Biochemistry, Federal University of Pernambuco, Recife, Brazil.

No abstract available

Publication types

Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Alleles
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Chromosome Aberrations
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Etoposide / therapeutic use
Female
Gene Expression
Genetic Predisposition to Disease*
Humans
Idarubicin / therapeutic use
Leukemia, Myeloid, Acute / diagnosis*
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality
Male
Middle Aged
Polymorphism, Single Nucleotide*
Prognosis
Retrospective Studies
Survival Analysis
Thioguanine / therapeutic use
Tumor Suppressor Protein p53 / genetics*

Substances

TP53 protein, human
Tumor Suppressor Protein p53
Cytarabine
Etoposide
Thioguanine
Idarubicin
Daunorubicin